On ‘International Mount Everest Day’ (29th May) ‘The Art Maze’, by Curator Marcus Schaefer, Unveils Artist Sacha Jafri’s Latest Masterpiece as a First Time Ever Event at Mount Everest
31.5.2022 09:00:00 EEST | Business Wire | Press release
‘The Art Maze’ World Tour, in partnership with UNESCO, is an unpresented collection of 50 UNESCO World Heritage Sites, created by celebrated Artist, Sacha Jafri, in celebration of UNESCO World Heritage Site’s 50th year anniversary and The Next 50, a year-long UNESCO campaign promoting interdisciplinary reflection on the future of the World’s Heritage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220530005345/en/
Jafri's Everest Painting Unveiled (Photo: AETOSWire)
Jafri, awarded by the UN for his humanitarian work raising over $140 million for charitable causes, is unveiling his ‘Sagarmatha National Park - Mount Everest’ painting, a spectacular 380cmx160cm three-canvas Triptych piece. With this project Jafri aims to reconnect humanity to our cultural heritage, our ancestral past and the beauty that surrounds us within our natural world, as well as shine a light on the important conversations and actions so desperately needed for the future of our world, in the areas of equality, sustainability & climate change.
Sacha Jafri, Artist & Philanthropist: “It is such an honour for me to partner with ‘The Art Maze’ and UNESCO using the power of art to reconnect with humanity in space and on earth.”
Marcus Schaefer, Art Visionary & Curator: “Feeling such a strong connection to this great country, we are so excited to unveil Sacha’s latest painting with the people of Nepal at the majestic Mount Everest.”
Michael Croft, Head of Office and Representative to Nepal at UNESCO: “As we listen to communities from the mountain regions and hear their perspective on tackling the dual challenges of climate change and sustainable tourism, we are at once motivated - and better informed - how best to fashion our own actions for change.”
UNESCO’s partnership with ‘The Art Maze’ and Sacha Jafri reinforces its mission of promoting inclusive, interdisciplinary dialogues related to climate change, heritage conservation, sustainable tourism, and the challenges these sites face in the context of climate change. In Nepal, UNESCO is working to bring together mountain community leaders as part of The Next 50 dialogues.
Raza Beig, Chairman of BoredPuma: “So excited to be able to announce my purchase of this monumental painting - I now own a piece of a living Indian master, Sacha Jafri, but also, the artistic expression of the world’s largest natural beauty - Mount Everest.”
In honour of this cause, Jafri is producing a signature print collection for art lovers who are keen to own a piece of his humanitarian journey. They can be found at: https://www.collection.theartmaze.com/
‘The Art Maze’ visits 18 countries across six continents of the world 2022-2024 with the next stop in Paris, September 2022, at UNESCO’s Headquarters commemorating the organisation’s 50th anniversary with all 50 of Jafri’s paintings on display.
Follow ‘The Art Maze’
WEBSITE:
www.theartmaze.com
@sachajafri @the.artmaze
Download Images & Films
HERE
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005345/en/
Contact information
Leidar
Lejo Johnny
Lejo.johnny@leidar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom